Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.53)
# 856
Out of 5,147 analysts
217
Total ratings
47.55%
Success rate
22.49%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $6.90 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $24.56 | +14.01% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $190.02 | -21.06% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $163.89 | -6.64% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $14.85 | -5.72% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $83.82 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $11.52 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $36.41 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $28.54 | +103.22% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $30.10 | +42.86% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $62.22 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.67 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $132.25 | +17.20% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.28 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $21.18 | +65.25% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $8.91 | +45.90% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.09 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.63 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $23.08 | +47.31% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $41.10 | +21.65% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $6.21 | -19.48% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.78 | +410.63% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.44 | +177.78% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $43.23 | +34.17% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.38 | +79,610.14% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $5.23 | +1,431.10% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.02 | +194.12% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $4.43 | +148.31% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $8.49 | +41.34% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $10.14 | +1,556.80% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $3.42 | +485.65% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $38.16 | +424.11% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.63 | +145.40% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.28 | +952.63% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.81 | +7,855.80% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.68 | +138.10% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $69.53 | -43.91% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $35.70 | -57.98% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.43 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $4.31 | +4,076.33% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.90
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $24.56
Upside: +14.01%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $190.02
Upside: -21.06%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $163.89
Upside: -6.64%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $14.85
Upside: -5.72%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $83.82
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.52
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.41
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $28.54
Upside: +103.22%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $30.10
Upside: +42.86%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $62.22
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.67
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $132.25
Upside: +17.20%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.28
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $21.18
Upside: +65.25%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $8.91
Upside: +45.90%
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.09
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.63
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $23.08
Upside: +47.31%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $41.10
Upside: +21.65%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $6.21
Upside: -19.48%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.78
Upside: +410.63%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.44
Upside: +177.78%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $43.23
Upside: +34.17%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.38
Upside: +79,610.14%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $5.23
Upside: +1,431.10%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.02
Upside: +194.12%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $4.43
Upside: +148.31%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $8.49
Upside: +41.34%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $10.14
Upside: +1,556.80%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $3.42
Upside: +485.65%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $38.16
Upside: +424.11%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.63
Upside: +145.40%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.28
Upside: +952.63%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.81
Upside: +7,855.80%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.68
Upside: +138.10%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $69.53
Upside: -43.91%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $35.70
Upside: -57.98%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.43
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $4.31
Upside: +4,076.33%